Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Now Rated “Reduce” by Wall Street Analysts

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has been given a consensus rating of “Reduce” by the twelve research firms that are currently covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a sell recommendation and seven have issued a hold recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $23.67.

A number of equities analysts recently weighed in on the stock. Citigroup restated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 17th. Berenberg Bank set a $24.00 target price on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday. Zacks Research raised shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. BNP Paribas Exane downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 price target on the stock. in a research report on Tuesday, July 28th. Finally, Truist Financial set a $25.00 price objective on Fresenius Medical Care AG & Co. KGaA in a research report on Wednesday, August 5th.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of NYSE:FMS opened at $22.27 on Friday. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The company has a market cap of $11.96 billion, a price-to-earnings ratio of 11.54, a price-to-earnings-growth ratio of 4.26 and a beta of 0.76. The company has a 50-day moving average price of $23.42 and a 200-day moving average price of $22.94. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $20.02 and a 12 month high of $27.64.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its earnings results on Monday, August 3rd. The company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.04. The company had revenue of $5.55 billion during the quarter, compared to analysts’ expectations of $5.48 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%. As a group, equities analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 2.25 EPS for the current year.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

Large investors have recently bought and sold shares of the business. Allworth Financial LP boosted its stake in Fresenius Medical Care AG & Co. KGaA by 31.5% during the second quarter. Allworth Financial LP now owns 3,552 shares of the company’s stock worth $80,000 after buying an additional 850 shares during the period. Integrated Wealth Concepts LLC purchased a new position in shares of Fresenius Medical Care AG & Co. KGaA during the second quarter worth approximately $91,000. EverSource Wealth Advisors LLC increased its holdings in Fresenius Medical Care AG & Co. KGaA by 50.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 4,135 shares of the company’s stock worth $93,000 after purchasing an additional 1,383 shares during the period. Parallel Advisors LLC increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 27.9% during the first quarter. Parallel Advisors LLC now owns 4,632 shares of the company’s stock valued at $104,000 after buying an additional 1,011 shares during the period. Finally, Hantz Financial Services Inc. increased its position in Fresenius Medical Care AG & Co. KGaA by 10.5% during the 4th quarter. Hantz Financial Services Inc. now owns 7,370 shares of the company’s stock valued at $176,000 after purchasing an additional 699 shares during the period. Institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney disease and kidney failure. The company provides dialysis care through a global network of outpatient clinics and supports patients with related medical services, including vascular access care, laboratory services and care coordination.

In addition to operating dialysis facilities, Fresenius Medical Care develops and manufactures products used in dialysis treatment.